id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-D-0616-0019,FDA,FDA-2010-D-0616,Guidance for Industry on Codevelopment of Two or More New Investigational Drugs for Use in Combination; Availability,Notice,Notice of Availability,2013-06-14T04:00:00Z,2013,6,2013-06-14T04:00:00Z,,2014-01-11T22:14:58Z,2013-14168,0,0,090000648131fe89
FDA-2010-D-0616-0020,FDA,FDA-2010-D-0616,Guidance for Industry on Codevelopment of Two or More New Investigational Drugs for Use in Combination,Other,Guidance,2013-06-14T04:00:00Z,2013,6,2013-06-14T04:00:00Z,,2024-11-12T05:16:20Z,,1,0,0900006481320325
FDA-2010-D-0616-0001,FDA,FDA-2010-D-0616,Draft Guidance for Industry; Availability: Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination,Notice,NAD-Notice of Availability of Data,2010-12-15T05:00:00Z,2010,12,2010-12-15T05:00:00Z,2011-02-15T04:59:59Z,2010-12-15T22:26:14Z,2010-31426,0,0,0900006480bb7048
FDA-2010-D-0616-0002,FDA,FDA-2010-D-0616,Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination - Draft Guidance,Other,GDL-Guidance (Supporting and Related Materials),2010-12-15T05:00:00Z,2010,12,2010-12-15T05:00:00Z,,2019-10-21T13:19:49Z,,0,0,0900006480bb7e80